Page last updated: 2024-11-12

n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide: MK-0364 is the (1S,2S)-isomer; a cannabinoid-1 receptor inverse agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11226090
CHEMBL ID220360
CHEBI ID177607
SCHEMBL ID304925
MeSH IDM0511666

Synonyms (50)

Synonym
HY-10013
n-[(2s,3s)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(triluoromethyl)pyridin-2-yl]oxypropanamide
CHEBI:177607
taranabant
mk-0364
mk0364
mk 0364
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
propanamide, n-((1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)-2-pyridinyl)oxy)-
taranbant
n-[(1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide
bdbm50200841
CHEMBL220360 ,
mk-0634
AKOS005145560
701977-09-5
D09009
taranabant (usan/inn)
taranabant [usan:inn]
x9u622s114 ,
n-((1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
unii-x9u622s114
CS-0289
taranabant [inn]
n-[(1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide
taranabant [who-dd]
taranabant [usan]
SCHEMBL304925
DTXSID60220464
n-[(1s,2s)-3-(4-chloro-phenyl)-2-(3-cyano-phenyl)-1-methyl-propyl]-2-methyl-2-(5-trifluoromethyl-pyridin-2-yloxy)-propionamide
1204240-86-7
n-[(2s,3s)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide
gtpl9231
701977-00-6
7dy ,
n-[(2s,3s)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide
NCGC00378803-02
tranabant (mk-0364)
taranabant (racemate)
n-[(1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide(mk 0364)
BCP21059
taranabant (mk-0364)
n-((2s,3s)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
DB06624
Q7685387
mk-0364 racemate
n-[(1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( mk 0364)
MS-29577
qlykjcmunuwago-gajhueqpsa-n
E98795

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Clinical adverse experiences associated with single doses of taranabant were generally mild and transient."( Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in health
Addy, C; Agrawal, N; Boyce, M; Cote, J; Cummings, C; Gottesdiener, K; Li, H; Li, S; Maes, A; Majumdar, A; Rosko, K; Rothenberg, P; Stoch, A; Stone, J; Wagner, J; Warrington, S; Yuan, J; Zhong, L, 2008
)
0.35
" The incidence of adverse experiences classified in the gastrointestinal, nervous, psychiatric, cutaneous and vascular organ systems were generally observed to be dose related with taranabant vs placebo."( A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Amatruda, JM; Aronne, LJ; Erondu, N; Gantz, I; Heymsfield, SB; Kaufman, KD; Meehan, AG; Molony, C; Moreno, M; Nayee, J; Shapiro, D; Sieberts, S; Suryawanshi, S; Tonstad, S, 2010
)
0.36
"Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences."( A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Amatruda, JM; Aronne, LJ; Erondu, N; Gantz, I; Heymsfield, SB; Kaufman, KD; Meehan, AG; Molony, C; Moreno, M; Nayee, J; Shapiro, D; Sieberts, S; Suryawanshi, S; Tonstad, S, 2010
)
0.36
" Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group."( A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Amatruda, JM; Erondu, N; Harp, JB; Heymsfield, SB; Johnson-Levonas, AO; Jones, ME; Kaufman, KD; Proietto, J; Rissanen, A; Suryawanshi, S; Yu, Q, 2010
)
0.36
" Incidences of adverse experiences in organ systems known to express CB1R were higher in taranabant groups."( A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Amatruda, JM; Erondu, N; Harp, JB; Heymsfield, SB; Johnson-Levonas, AO; Jones, ME; Kaufman, KD; Proietto, J; Rissanen, A; Suryawanshi, S; Yu, Q, 2010
)
0.36
" After 52 weeks, the incidences of adverse experiences classified in the gastrointestinal (diarrhoea, nausea, vomiting), nervous system-related (dizziness, sensory-related), and psychiatric (irritability, depression-related) organ systems were numerically higher or statistically significantly higher in all taranabant groups compared with the placebo group."( A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
Amatruda, JM; Chou, M; Erondu, N; Fujioka, K; Gantz, I; Heymsfield, SB; Hollander, P; Johnson-Levonas, AO; Kaufman, KD; Kipnes, MS; Lu, K; Seck, T; Shapiro, D; Shentu, Y; Suryawanshi, S, 2010
)
0.36
"After 36 and 52 weeks, treatment with taranabant at the 1- and 2-mg doses led to clinically significant weight loss and improvement in glycaemic parameters in overweight and obese patients with T2DM that was associated with dose-related increases in adverse experiences."( A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
Amatruda, JM; Chou, M; Erondu, N; Fujioka, K; Gantz, I; Heymsfield, SB; Hollander, P; Johnson-Levonas, AO; Kaufman, KD; Kipnes, MS; Lu, K; Seck, T; Shapiro, D; Shentu, Y; Suryawanshi, S, 2010
)
0.36
"Database search identified all clinical trials published up to May 2018 that reported rimonabant and taranabant treatment for at least one month and detailed the GI adverse events (AEs)."( Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.
Fabisiak, A; Fabisiak, N; Fichna, J; Storr, M; Włodarczyk, M, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" Taranabant has pharmacokinetic characteristics suitable for a once-daily dosing regimen."( Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in health
Addy, C; Agrawal, N; Boyce, M; Cote, J; Cummings, C; Gottesdiener, K; Li, H; Li, S; Maes, A; Majumdar, A; Rosko, K; Rothenberg, P; Stoch, A; Stone, J; Wagner, J; Warrington, S; Yuan, J; Zhong, L, 2008
)
0.35
"5-, and 10-mg doses, with an accumulation half-life ranging from 15 to 21 hours."( Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy, C; Agrawal, N; Cote, J; de Hoon, J; De Lepeleire, I; Depré, M; Dunbar, S; Gottesdiener, K; Knops, A; Li, H; Li, S; Maes, A; Majumdar, A; Rosko, K; Rothenberg, P; Stoch, A; Van Dyck, K; Van Hecken, A; Wagner, J; Yuan, J; Zhong, L, 2008
)
0.35
"5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on day 21 of each cycle for determination of AUC0-24 h and Cmax of ethinyl estradiol and norelgestromin."( Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Dunbar, S; Johnson-Levonas, AO; Lasseter, KC; Li, S; Miller, DL; Rosko, K; Schwartz, JI; Wagner, JA; Yuan, J, 2009
)
0.35
" This study was designed to establish if this combination of therapy has the potential of a significant pharmacokinetic interaction."( Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Denker, AE; Dunbar, S; Lewis, NM; Li, S; Morelli, G; Taggart, W; Vessey, LK; Wagner, JA; Yuan, J, 2009
)
0.35
"This study assessed the potential pharmacokinetic interaction and safety/tolerability of taranabant and phentermine coadministration."( Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Addy, C; Chodakewitz, J; Johnson-Levonas, AO; Jumes, P; Li, H; Li, S; Maes, A; Rosko, K; Stoch, SA; Wagner, JA, 2009
)
0.35
" A population model was constructed to facilitate the estimation of pharmacokinetic parameters and to identify the influence of selected covariates."( Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.
Addy, C; Cirincione, B; Erondu, N; Gantz, I; Hartford, A; Li, H; Li, XS; Morgan, J; Nielsen, J; Stone, J; Wagner, J, 2010
)
0.36
"Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds."( Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Azzara, AV; Baska, RA; Behnia, K; Carlson, KE; Cullen, MJ; Devenny, JJ; Ellsworth, BA; Everlof, GG; Ewing, WR; Godonis, HE; Gu, Z; Gudmundsson, O; Harvey, SJ; Johnghar, S; Kang, L; Keim, WJ; Lee, N; Murphy, BJ; Murugesan, N; Pelleymounter, MA; Ranasinghe, A; Rohrbach, KW; Sher, PM; Sitkoff, DF; Stetsko, PI; Sulsky, RB; Thomas, MA; Wu, G; Wu, X; Yang, Y; Yu, G; Zhu, Y; Zuvich, E, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"The goal of this study was to demonstrate that MK-0364 solid dispersions can be developed as a means to increase the solubility and bioavailability of a poorly water-soluble drug, MK-0364."( Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364.
McKelvey, C; Moser, J; Rege, B; Sotthivirat, S; Xu, W; Zhang, D, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Taranabant has pharmacokinetic characteristics suitable for a once-daily dosing regimen."( Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in health
Addy, C; Agrawal, N; Boyce, M; Cote, J; Cummings, C; Gottesdiener, K; Li, H; Li, S; Maes, A; Majumdar, A; Rosko, K; Rothenberg, P; Stoch, A; Stone, J; Wagner, J; Warrington, S; Yuan, J; Zhong, L, 2008
)
0.35
" Following a 10-day wash out, they started a 19-day taranabant dosing regimen (6 mg once daily from day -14 to day 5) designed to establish and maintain steady-state levels of taranabant."( Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Denker, AE; Dunbar, S; Lewis, NM; Li, S; Morelli, G; Taggart, W; Vessey, LK; Wagner, JA; Yuan, J, 2009
)
0.35
" The potential solid dispersions would enable an oral solid dosage form as a monotherapy or combination product of MK-0364."( Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364.
McKelvey, C; Moser, J; Rege, B; Sotthivirat, S; Xu, W; Zhang, D, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.84870.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency2.39190.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.89990.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency2.39190.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.00030.00011.753610.0000AID342292
Cannabinoid receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00030.00020.660910.0000AID612501
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)0.00310.00010.275310.0000AID1656364; AID274572; AID292507; AID318853; AID318854; AID318855; AID318856; AID318857; AID318858; AID318864; AID319062; AID342292; AID352158; AID446983; AID476812; AID479936; AID484537; AID495001
Cannabinoid receptor 1Homo sapiens (human)Ki0.00030.00010.50779.6000AID428189
Cannabinoid receptor 2 Homo sapiens (human)IC50 (µMol)0.50870.00081.58409.8000AID274573; AID345341; AID446987; AID479937
Cannabinoid receptor 2 Homo sapiens (human)Ki0.29000.00000.415610.0000AID428190
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)14.20000.00091.901410.0000AID501827
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Homo sapiens (human)EC50 (µMol)0.00240.00010.12752.2400AID274585; AID446984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (53)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (102)

Assay IDTitleYearJournalArticle
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID501801Antiobesity activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of body weight at 10 mg/kg, po qd for 14 days2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID495001Displacement of [3H]CP55490 from human recombinant cannabinoid CB1 receptor expressed in CHO cells2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
AID274572Inhibition of [3H]CP-55940 binding to human recombinant CB1 receptor in CHO cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501813Cmax in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID472956Suppression of food intake in DIO rat at 1 mg/kg, po measured 18 hrs post dose on day 14 relative to control2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
AID428190Displacement of [3H]rimonabant from human CB2 receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
AID318864Displacement of [3H]SR-141716 from human wild type CB1R expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID274584Half life in rhesus monkey at 0.2 mg/kg, iv and 0.4 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID274576Drug level in Sprague-Dawley rat brain at 1 mg/kg, iv after 1 hr2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501996Inhibition of CYP2D6 in human liver microsomes after 30 mins2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID425924Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as serum glucose level at 3 mg/kg, po administered once daily for 14 days (Rvb = 9.52+/-0.38 mmol/mL)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID274585Inverse agonist activity at human recombinant CB1 receptor assessed as inhibition of forskolin-induced cAMP production in CHO cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID479936Inhibition of cannabinoid CB1 receptor2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
AID501817Half life in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID342285Plasma clearance in rat at 2 mg/kg, po2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID318860Ratio of IC50 for human CB1R W279A mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID479937Inhibition of cannabinoid CB2 receptor2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
AID274591Protein binding in human liver microsome2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501811Tmax in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID274587Inhibition of CP-55940-induced decrease in body temperature in Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID274586Activity at human recombinant CB1 receptor assessed as inhibition of forskolin-induced cAMP production in CHO cells relative to CP-559402006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID425926Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as serum triglyceride level at 3 mg/kg, po administered once daily for 14 days (Rvb = 1.42+/-0.04 mmol/mL)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID479934Inverse agonist activity at human recombinant cannabinoid CB2 receptor expressed in CHO cellssassessed as inhibition of forskolin-stimulated increase in intracellular cAMP level2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
AID501814Clast in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID318858Displacement of [3H]CP-55940 from human CB1R F170L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID274575Half life in Sprague-Dawley rat at 1 mg/kg, iv and 2 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID476793Suppression of cumulative food intake in rat at 1 mg/kg, po after 13 days relative to control2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
AID274582Half life in dog at 0.2 mg/kg, iv and 0.4 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501824Inhibition of CYP2C9 in human liver microsomes after 30 mins2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID342290Cmax in rat at 2 mg/kg, po2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID274588Reduction in Sprague-Dawley rat body weight at 0.3 mg/kg, po after 14 days relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501826Inhibition of CYP3A4 in human liver microsomes after 30 mins2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID342292Displacement of [3H]CP-55940 from human CB1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID274574Bioavailability in Sprague-Dawley rat at 1 mg/kg, iv and 2 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501821Oral bioavailability in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID345342Selectivity ratio of IC50 for human CB2 receptor to IC50 for Sprague-Dawley rat CB1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
AID345340Displacement of [3H]CP-55940 from CB1 receptor in Sprague-Dawley rat cerebellum by liquid scintillation spectrometry2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
AID501823Inhibition of CYP1A2 in human liver microsomes after 30 mins2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID318853Displacement of [3H]CP-55940 from human wild type CB1R expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID484542Toxicity in diet-induced obese rat assessed as change in body weight at 3 mg/kg, po after 18 hrs (RVb = 10 g)2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.
AID446985Selectivity ratio of IC50 of human recombinant CB1 receptor to IC50 of human recombinant CB2 receptor2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
AID318854Displacement of [3H]CP-55940 from human CB1R F200L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID446983Displacement of [3H]CP-55940 from recombinant human CB1 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
AID318857Displacement of [3H]SR-141716 from human CBR1 S383A mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID425925Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as serum cholesterol level at 3 mg/kg, po administered once daily for 14 days (Rvb = 5.35+/-0.12 mmol/mL)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID428189Displacement of [3H]rimonabant from human CB1 receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
AID318855Displacement of [3H]CP-55940 from human CB1R W279A mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID425912Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as body weight at 3 mg/kg, po administered once daily for 14 days (Rvb=41.90 g)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID318859Ratio of IC50 for human CB1R F200L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID479933Inverse agonist activity at human recombinant cannabinoid CB1 receptor expressed in CHO cellssassessed as inhibition of forskolin-stimulated increase in intracellular cAMP level2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
AID274573Inhibition of [3H]CP-55940 binding to human recombinant CB2 receptor in CHO cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501812Cmax in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID318856Displacement of [3H]CP-55940 from human CB1R K192L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID352157Antiobesity activity in diet-induced obese Sprague-Dawley rat model assessed as suppression of overnight body weight change at 3 mg/kg, po administered 1 hr before dark cycle for 14 days measured after 18 hrs of last dose2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
AID345341Displacement of [3H]WIN-55212-2 from human CB2 receptor expressed in CHOK1 cells by liquid scintillation spectrometry2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
AID318861Ratio of IC50 for human CB1R K192L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID446984Inverse agonist activity at human CB1 receptor assessed as forskolin-induced cAMP level by adenylyl cyclase activation flash plate assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
AID274580Selectivity for human CB1 receptor over CB2 receptor2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID446987Displacement of [3H]CP-55940 from recombinant human CB2 receptor expressed in CHO cell2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
AID319062Displacement of [3H]CP-55940 from human CB1R expressed in HEK293 cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
AID274577Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 1 hr2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1656364Inhibition of radiolabeled CP5549 binding to human Cannabinoid receptor 1 expressed in CHO cells by competition assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Designing around Structural Alerts in Drug Discovery.
AID501827Inhibition of human ERG at holding potential of -80 mV to +40 mV2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID501816Half life in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID501820AUC (0 to infinity) in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID501815Clast in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID501822Ratio of drug level in brain to plasma in Sprague-Dawley rat2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID476792Reduction of body weight in rat at 1 mg/kg, po after 13 days relative to control2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
AID501818Clearance in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID484537Binding affinity to human CB1 receptor2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.
AID292508Distribution coefficient, log D at pH 7.32007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
AID318863Ratio of IC50 for human CB1R F170L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID612501Displacement of [3H]SR141716A from rat brain CB1 receptor at pH 7.4 after 1 hr by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists.
AID274583Bioavailability in rhesus monkey at 0.2 mg/kg, iv and 0.4 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID476819Reduction of body weight in DIO rat assessed as weight change at 1 mg/kg, po daily measured 18 hrs post dose on day 132010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
AID274581Bioavailability in dog at 0.2 mg/kg, iv and 0.4 mg/kg, po2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID476812Inhibition of human CB1 receptor2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
AID501829Mutagenic activity in Salmonella Typhimurium TA100 assessed as number of spontaneous and drug-induced revertants after 48 hrs by Ames test2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID352156Antiobesity activity in diet-induced obese Sprague-Dawley rat model assessed as suppression of overnight food intake at 3 mg/kg, po administered 1 hr before dark cycle for 14 days measured after 17 hrs of last dose2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
AID501807Antiobesity activity in diet-induced obesity Sprague-Dawley rat model assessed as reduction of body weight administered at 10 mg/kg, po qd for 13 days2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID484543Toxicity in diet-induced obese rat assessed as suppression in food intake at 3 mg/kg, po after 18 hrs2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.
AID425928Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as serum LDL-cholesterol level at 3 mg/kg, po administered once daily for 14 days (Rvb=0.84+/-0.03 mmol/mL)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID274589Reduction in Sprague-Dawley rat body weight at 1 mg/kg, po after 14 days relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID292507Displacement of [3H]CP-55940 from human recombinant CB1R expressed in CHO cells2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
AID1177622Receptor occupancy at CB1 receptor in diet-induced obese rat assessed as weight loss2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Peripherally restricted CB1 receptor blockers.
AID318862Ratio of IC50 for human CB1R S383A mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID352158Inverse agonist activity at cannabinoid CB1 receptor2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
AID274590Reduction in Sprague-Dawley rat body weight at 3 mg/kg, po after 14 days relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
AID501819AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID425927Antiobesity activity in TBU8 high fat diet-induced obese C57/BL6 mouse assessed as serum HDL-cholesterol level at 3 mg/kg, po administered once daily for 14 days (Rvb=4.42+/-0.08 mmol/mL)2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
AID501828Induction of DNA damage up to 50 uM after 2 hrs by comet assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
AID342291Oral bioavailability in rat2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID342289Half life in rat plasma at 2 mg/kg, po2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID1138123Elimination half life in human2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
AID1346728Human CB2 receptor (Cannabinoid receptors)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
AID1346701Human CB1 receptor (Cannabinoid receptors)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's27 (48.21)29.6817
2010's26 (46.43)24.3611
2020's3 (5.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.07 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (22.81%)5.53%
Reviews7 (12.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (64.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension [NCT00430742]Phase 3600 participants (Actual)Interventional2006-11-30Terminated(stopped due to The overall profile does not support development for obesity)
A Study to Assess the Efficacy and Tolerability of Taranabant in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension [NCT00420589]Phase 31,000 participants (Actual)Interventional2006-10-31Terminated(stopped due to The overall profile does not support development for obesity)
A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension [NCT00131391]Phase 32,400 participants (Actual)Interventional2005-07-31Terminated(stopped due to The overall profile does not support development for obesity)
An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients [NCT00131430]Phase 2/Phase 3500 participants (Actual)Interventional2005-08-31Completed
A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients [NCT00109148]Phase 2500 participants (Actual)Interventional2004-07-31Completed
A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation [NCT00109135]Phase 2300 participants (Actual)Interventional2005-01-31Completed
A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension [NCT00131404]Phase 32,400 participants (Actual)Interventional2005-09-30Terminated(stopped due to The overall profile does not support development for obesity)
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Obese Patients and in Overweight Patients With Obesity-Related Co-Morbidities, Followed by a 1-Year Extension [NCT00384605]Phase 31,000 participants (Actual)Interventional2006-10-31Terminated(stopped due to The overall profile does not support development for obesity)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]